anti-GD2 monoclonal antibody BCD-245

A monoclonal antibody directed against the tumor-associated antigen (TAA) disialoganglioside (GD2; GD-2), with potential antineoplastic activity. Upon administration, anti-GD2 monoclonal antibody BCD-245 may induce cytotoxicity in GD2-expressing tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC). GD2 is overexpressed on the surface of neuroblastoma (NB) cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells.